Resource for Lung Biomarker Support Launches January 24
NeoTYPE® Lung Tumor
Profiles with positive results will include a new Patient Resource Page
beginning Monday, January 24th. Launched in partnership with Biomarker
Collaborative, this resource marks the first time biomarker education for
patients and support group listings will be included in laboratory reports. We
expect this page will facilitate provider-patient conversations about
biomarker-based care and provide patients with access to support and advocacy
Patient Resource Page will appear as the last page of the NeoTYPE® Lung
Tumor Profile report and it provides a space for the provider or patient to
write in the most important biomarker. To view a sample report, please contact
your local Business Manager or Internal Account Executive. We look forward to
Molecular- Please note a change in the effective date below
Effective Monday, January 31st,
clients placing online orders can select MLH1 Promoter Methylation Analysis as a
reflex option for negative result BRAF Mutation Analysis specimens. This will
mirror the checkbox already available on the Single Biomarkers & Consults
Solid Tumor Pathology Requisition. This reflex allows for hybrid approach when
screening colorectal cancer patients for Lynch syndrome, prior to any
additional germline testing being requested.
interface-related test changes occurring on Monday, January 31st, click here
for a downloadable document to view the impacted interface test codes.
If you have interface questions, please contact InterfaceTeam@Neogenomics.com.